Price
No data yet.
Social Signal Score
Analyst Ratings
13 analystsRevenue
$3.09M+496.91%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Ofer Gonen
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 121
- Beta
- 0.14
- Country
- IL
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -2.16
Financials
Revenue
$3.09M+496.9%Net Income
$-7.39MEBITDA
$-9.06MFree Cash Flow
$-10.06MEPS (diluted)
$-0.57Shares Outstanding (diluted)
12.88M+312.7%Operating Expenses
$9.79MCash & Debt
$35.34MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $16.96M | $-23.88M | $-2.10 |
| 2024 | $20.22M | $-30.22M | $-3.03 |
| 2023 | $18.69M | $-6.72M | $-0.75 |
| 2022 | $26.50M | $-19.60M | $-3.93 |
| 2021 | $23.76M | $-13.55M | $-3.48 |
| 2020 | $21.76M | $-9.20M | $-2.38 |
| 2019 | $31.79M | $4.96M | $1.26 |
| 2018 | $3.40M | $-1.06M | $-0.28 |
| 2017 | $2.50M | $-22.15M | $-6.64 |
| 2016 | $1.56M | $-18.89M | $-6.05 |
| 2015 | $601.0K | $-22.09M | $-7.13 |
| 2014 | $259.0K | $-18.88M | $-6.65 |
| 2013 | $0.00 | $-15.35M | $-5.28 |
| 2012 | $0.00 | $10.94M | $3.76 |
Valuation
MDWDhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-68.53%Social Signal Score
Mentions (6)
- Newsglobenewswire.com·14d ago·Neutral
MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid® MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid ®
View source ↗ - Newsglobenewswire.com·22d ago·Neutral
…ssessment and enrollment completion remain on track for end of the first quarter of 2027 YAVNE, Israel, September 14, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the independent Data and Safety Monitoring Board (DSMB) completed its pre-specified periodic safety review of the ongoing Phase III VALUE study evaluating the safety and efficacy of EscharEx® in patients with venous leg ulcers (V…
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference MediWound to Present at the H.C. Wainwright 28 th Annual Global Investment Conference YAVNE, Israel, September 2, 2026 -- MediWound Ltd.
View source ↗ - Newsseekingalpha.com·53d ago·Positive
MediWound Ltd. (MDWD) Q2 2026 Earnings Call Transcript MediWound Ltd. (MDWD) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·53d ago·Neutral
MediWound Q2 Earnings Call Highlights MediWound NASDAQ: MDWD reported second-quarter 2026 revenue of $3.1 million, down from $5.7 million a year earlier, as the company continued investing in its Phase III EscharEx chronic-wound program and expanded development work around its NexoBrid burn treatment.
View source ↗ - Newszacks.com·54d ago·Neutral
MediWound (MDWD) Reports Q2 Loss, Beats Revenue Estimates MediWound (MDWD) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to a loss of $1.23 per share a year ago.
View source ↗
Earnings
Thu, Nov 19(in 6 weeks)
Consensus estimate $-0.71 per share
Typical surprise +39.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.77 vs $-0.76miss
- Wed, May 27$-0.23 vs $-0.65beat
- Thu, Mar 5$-0.56 vs $-0.65beat
- Thu, Nov 20$-0.24 vs $-0.81beat
- Thu, Aug 14$-1.23 vs $-0.55miss
- Wed, May 21$-0.07 vs $-0.65beat
Estimates and results for MDWD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MDWD officers and directors.
- Bought
- $143k
- Sold
- $82k
7 trades
4 trades
- Rubinstein Samuelbought
- Rubinstein Samuelsold
- Hess Shmuelsold
- Hess Shmuelsold
- Hess Shmuelsold
- Shamir Nachumbought
- Shamir Nachumbought
- Fox David Mortonbought
89 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in MDWD.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.